

Q3 2021 Results

November 10, 2021



Forward Looking Statements and Non-GAAP Financial Measures

This presentation contains forward-looking statements that reflect management's expectations about future events and the Company's operating plans and performance and speak only as of the date hereof. You can identify these forward-looking statements by the use of forward-looking words such as "will," "may," "plan," "estimate," "project," "believe," "anticipate," "expect," "intend," "should," "would," "could," "target," "goal," "continue to," "positioned to," "are confident" or the negative version of those words or other comparable words. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including our 2021 outlook, are forward-looking statements. Any forward-looking statements contained in this presentation are based upon our historical performance and on our current plans, estimates and expectations of the Company's future performance and the future performance of the markets in which the Company operates in light of information currently available to us. The inclusion of this forward-looking information should not be regarded as a representation by us that the future plans, estimates or expectations contemplated by us will be achieved. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, without limitation, any disruption in the availability or supply of ethylene oxide ("EO") or cobalt-60 ("Co-60"); changes in industry trends, environmental, health and safety regulations or preferences; the impact of current and future legal proceedings and liability claims, including litigation related to purported exposure to emissions of EO from our facilities in Illinois, Georgia and New Mexico and the possibility that other claims will be made in the future relating to these or other facilities; our ability to increase capacity at existing facilities, renew leases for our facilities and build new facilities in a timely and cost-effective manner; intense competition for qualified employees in the industries in which we operate; the risks of doing business internationally; and any inability to pursue strategic transactions or find suitable acquisition targets. For additional discussion of these risks and uncertainties, please refer to those described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and the Company's other filings with the SEC, including its Quarterly Reports on Form 10-Q, including under the headings "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements".

This presentation includes Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Total Net Debt and Net Leverage Ratio, which are unaudited financial measures not based on any standardized methodology prescribed by GAAP. Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Total Net Debt and Net Leverage Ratio may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Total Net Debt and Net Leverage Ratio should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. See the Appendix for a reconciliation of net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA, a reconciliation of GAAP EPS, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EPS, and a reconciliation of total debt, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Total Net Debt and Net Leverage.

The Sotera Health name, our logo and other trademarks mentioned in this presentation are the property of their respective owners. All Company data and financial information included in this presentation is as of September 30, 2021, unless otherwise stated.

Speakers



Michael B. Petras, Jr.
Chairman and Chief Executive Officer



Scott J. Leffler
Chief Financial Officer and Treasurer

How we do business

Our values



Safety

We are uncompromising in our commitment to health and well-being



Customer focus

We are driven to fulfill our customers' needs with the highest quality and care



People

We value our people who are part of a global team that is diverse, respectful, passionate and collaborative



Integrity

We are honest, reliable and accountable in everything we do



Excellence

We exceed the expectations of our stakeholders and continue to improve and innovate in everything we do

Differentiated, mission-critical services model



We are driven by our mission: Safeguarding Global Health®

Our Mission: Safeguarding Global Health®

Our purpose is greater than our products and services - the **integrity, safety and excellence** of our work are at the heart of countless healthcare experiences and touch the lives of millions across the globe.



Recently one of our **Sterigenics** facilities rapidly sterilized an artificial heart for a patient in Spain



Sterigenics sterilizes vials, stoppers and swabs for the COVID-19 vaccine



Nelson Labs has tested the effectiveness of masks used for safety during the pandemic



Nelson Labs tests the effectiveness of most hand sanitizers and disinfectants used in homes and hospitals



Nordion supplies the Cobalt-60 used in Gamma Knife® surgery to treat brain tumors

Highlights

Business & Market Update

- Steady demand for Sterigenics and Nordion products and services
- Slow recovery in medical device testing and reduced demand in PPE testing
- Pandemic-related impacts persist on medical device supply chain, inflation and labor

Q3 2021 Financial Performance

- Revenue: increased 13% to \$226M
- Adjusted EBITDA⁽¹⁾: increased 16% to \$117M
- Adjusted EPS⁽¹⁾: increased \$0.12 to \$0.21

Capital

- Q3 2021 redemption of \$100M Senior Secured First-Lien Notes due in 2026
- Net leverage⁽¹⁾ improved to 3.6x
- Capital deployment focus remains on organic growth investments, strategic M&A and deleveraging

Strategic & Other Initiatives



- Launch of cross segment Expert Advisory Services organization
- Closed acquisition of Regulatory Compliance Associates on November 4, 2021
- 2 European facility expansions went live in the quarter and new E-beam installed in US

(1) For a reconciliation of GAAP to non-GAAP results, please refer to Non-GAAP Financial Measures provided in the Appendix.



Q3 & YTD 2021 Financial Performance - Consolidated

In millions, except Adjusted EPS



Revenue



Adjusted EBITDA⁽¹⁾



Adjusted EPS⁽¹⁾⁽³⁾





(1) We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income. Please refer to Non-GAAP Financial Measures provided in the Appendix.

(2) Adjusted EBITDA margin, which is equal to Adjusted EBITDA divided by net revenues. Please refer to Non-GAAP Financial Measures provided in the Appendix.

(3) Adjusted EPS is defined as Adjusted Net Income divided by the weighted average number of diluted shares outstanding. Please refer to Non-GAAP Financial Measures provided in the Appendix.

Q3 & YTD 2021 Financial Performance - Sterigenics

In millions




- Q3 2021 revenue and segment income growth driven by organic volume and favorable pricing
- Segment margin expansion for Q3 2021 driven by improved operating leverage
- Continued progress on strategic capital investments

(1) Segment income is defined to exclude, among other things, depreciation and amortization. Please refer to our consolidated financial statements for more information.

(2) Segment income margin.

Q3 & YTD 2021 Financial Performance - Nordion

In millions




- Q3 2021 revenue and segment income growth driven by timing of Cobalt-60 shipments, pricing and favorable foreign exchange impact
- Segment margin expansion for Q3 2021 driven by favorable operating leverage

(1) Segment income is defined to exclude, among other things, depreciation and amortization. Please refer to our consolidated financial statements for more information.

(2) Segment income margin.

Q3 & YTD 2021 Financial Performance - Nelson Labs

In millions





- Q3 2021 revenue decline driven by reduced demand for PPE-related testing, partly offset by revenue contribution from the BioScience Labs acquisition
- Decline in Q3 2021 segment margins driven by negative mix associated with lower PPE-related testing and acquisition of BioScience Labs

(1) Segment income is defined to exclude, among other things, depreciation and amortization. Please refer to our consolidated financial statements for more information.

(2) Segment income margin.

Capital Expenditures and Liquidity

In millions



- Continued investment in Sterigenics facility expansions and enhancements
- Progressing on Nordion Cobalt-60 supply development projects

- Continued strong liquidity position after funding paydown of \$100M Notes
- No outstanding borrowings on revolving credit facility


(1) Excludes any Capital Expenditures included in accounts payable or accruals at the end of the period.

(2) Revolving availability is calculated as maximum facility size less letters of credit.

(3) Maximum facility size was \$347.5M as of 12/31/20 and 9/30/21.


Deleveraging and Interest Expense

Net Leverage Reduction⁽¹⁾



- Consistent reduction in net leverage in every quarter since IPO
- Committed to deleveraging, with long-term target net leverage range of 2.0x - 4.0x⁽²⁾

Interest Expense Reduction



- YTD 2021 interest expense savings of \$108M
- Current annual run rate of ~\$70M⁽³⁾ after giving effect to Q3 2021 debt paydown

(1) For a reconciliation of GAAP to non-GAAP results, please refer to Non-GAAP Financial Measures provided in the Appendix.

(2) Long-term target is forward-looking and reflects expectations as of November 10, 2021. Sotera Health assumes no obligation to update this statement. Results may be materially different and are affected by many factors detailed in Sotera Health's SEC filings, including Sotera Health's 2020 Form 10-K.

(3) Based on interest rates as of November 10, 2021.

2021 Outlook

On the following slide, Sotera Health presents an overview of its full-year 2021 Outlook, including certain non-GAAP measures. As outlined in the Company's November 10, 2021 press release, Sotera Health does not provide a reconciliation of the forward-looking Adjusted EBITDA and Adjusted EPS outlook to the most directly comparable GAAP measure, as this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs.

2021 Guidance⁽¹⁾

	Initial Guidance	Guidance Raised	Guidance Narrowed	
	3/9/2021	8/12/2021	11/10/2021	YoY%
Revenue	\$890M to \$920M	\$920M to \$940M	\$920M to \$930M	+12% to +14%
Adj EBITDA ⁽²⁾	\$465M to \$485M	\$475M to \$490M	\$475M to \$480M	+13% to +14%
Tax Rate	~28%	~28%	~28%	~-6%
Adj EPS ⁽²⁾	\$0.78 to \$0.86	\$0.87 to \$0.91	\$0.87 to \$0.88	+107% to +110%
Weighted Avg. Diluted Shares	281M to 283M	279M to 281M	279M to 280M	+17% to +18%
Capital Expenditures	\$100M - \$110M	\$100M - \$110M	\$90M - \$100M	+68% to +87%
Net Leverage	Approximately $\frac{3}{4}$ turn ⁽³⁾ of deleveraging	Approximately $\frac{3}{4}$ turn ⁽³⁾ of deleveraging	Approximately $\frac{3}{4}$ turn ⁽³⁾ of deleveraging	

(1) The guidance provided above contains a number of assumptions, including, among others, the Company's current expectations regarding the impact of the COVID-19 pandemic including the rate of recoveries of elective procedures and new product development testing and that foreign exchange rates remain constant for the remainder of 2021. The information presented here is forward-looking and reflects expectations as of November 10, 2021. Sotera Health assumes no obligation to update this statement. Results may be materially different and are affected by many factors detailed in Sotera Health's SEC filings, including Sotera Health's 2020 Form 10-K.

(2) For a reconciliation of GAAP to non-GAAP results, please refer to Non-GAAP Financial Measures provided in the Appendix.

(3) One turn is equivalent to trailing 12-months of Adjusted EBITDA.

Appendix

Non-GAAP Financial Measures

(unaudited) (\$'s in thousands, except per share amounts)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2021	2020	2021	2020
Net income	\$ 27,444	\$ 629	\$ 81,124	\$ 5,895
Amortization of intangibles	21,239	20,200	65,299	59,824
Share-based compensation ^(a)	3,547	901	10,489	4,019
(Gain) loss on foreign currency and embedded derivatives ^(b)	1,881	(6,035)	885	(4,791)
Acquisition and divestiture related charges, net ^(c)	(2,662)	681	(2,003)	2,970
Business optimization project expenses ^(d)	244	685	780	2,484
Plant closure expenses ^(e)	266	1,166	1,564	2,388
Loss on extinguishment of debt ^(f)	6,365	—	20,677	—
Professional services relating to EO sterilization facilities ^(g)	9,449	11,730	33,492	25,370
Accretion of asset retirement obligation ^(h)	598	494	1,751	1,476
COVID-19 expenses ⁽ⁱ⁾	109	16	596	2,363
Income tax benefit associated with pre-tax adjustments ^(j)	(9,776)	(8,494)	(32,772)	(24,854)
Adjusted Net Income	58,704	21,973	181,882	77,144
Interest expense, net	18,140	55,330	58,585	167,142
Depreciation ^(k)	16,395	15,901	47,457	47,334
Income tax provision applicable to Adjusted Net Income ^(l)	23,435	7,281	68,630	15,177
Adjusted EBITDA^(m)	\$ 116,674	\$ 100,485	\$ 356,554	\$ 306,797
Net Revenues	\$ 226,164	\$ 200,028	\$ 690,229	\$ 601,313
Adjusted EBITDA Margin	51.6 %	50.2 %	51.7 %	51.0 %
Weighted average number of shares outstanding:				
Basic	279,381	232,400	279,097	232,400
Diluted	279,560	232,400	279,253	232,400
Earnings per share:				
Basic	\$ 0.10	\$ —	\$ 0.29	\$ 0.02
Diluted	0.10	—	0.29	0.02
Adjusted earnings per share:				
Basic	\$ 0.21	\$ 0.09	\$ 0.65	\$ 0.33
Diluted	0.21	0.09	0.65	0.33

Non-GAAP Financial Measures

- (a) Represents non-cash share-based compensation expense.
- (b) Represents the effects of (i) fluctuations in foreign currency exchange rates, primarily related to remeasurement of intercompany loans denominated in currencies other than subsidiaries' functional currencies, and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
- (c) Represents (i) certain direct and incremental costs related to the acquisitions of the noncontrolling interests in our China subsidiaries and BioScience Labs in 2021, Iotron Industries in July 2020 and Nelson Labs Fairfield in 2018 (including the first quarter 2021 gain on the mandatorily redeemable noncontrolling interest), and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018, and (iv) a \$3.4 million gain recognized in the third quarter of 2021 related to the settlement of an insurance claim for Nordion that existed at the time of our acquisition of the business in 2014.
- (d) Represents professional fees, contract termination and exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integration of recent acquisitions, the Sotera Health rebranding, operating structure realignment and other process enhancement projects.
- (e) Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility.
- (f) Represents expenses incurred in connection with the repricing of our Term Loan in January 2021 and full redemption of the First Lien Notes in August 2021 including accelerated amortization of prior debt issuance and discount costs.
- (g) Represents professional fees related to litigation associated with our EO sterilization facilities and other related professional fees.
- (h) Represents non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.
- (i) Represents non-recurring costs associated with the COVID-19 pandemic, including incremental costs to implement workplace health and safety measures. For the nine months ended September 30, 2020, costs also included donations to related charitable causes, and special bonuses for front-line personnel working on-site during lockdown periods.
- (j) Represents the tax benefit or provision associated with the reconciling items between net income and Adjusted Net Income. To determine the aggregate tax effect of the reconciling items, we utilized statutory income tax rates ranging from 0% to 35%, depending upon the applicable jurisdictions of each adjustment.
- (k) Includes depreciation of Co-60 held at gamma irradiation sites.
- (l) Represents the difference between income tax expense or benefit as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (j).
- (m) \$20.8 million and \$21.3 million of the adjustments for the three months ended September 30, 2021 and 2020, respectively, and \$63.3 million and \$62.0 million of the adjustments for the nine months ended September 30, 2021 and 2020, respectively, are included in cost of revenues, primarily consisting of amortization of intangibles, depreciation, and accretion of asset retirement obligations.

Non-GAAP Financial Measures

<i>(unaudited)</i> <i>(\$'s in thousands)</i>	<u>Year Ended December 31,</u>		<u>As of March 31,</u>	<u>As of June 30,</u>	<u>As of September 30,</u>
	<u>2019</u>	<u>2020</u>	<u>2021</u>	<u>2021</u>	<u>2021</u>
Current portion of long-term debt	\$ 16,331	\$ -	\$ -	\$ -	\$ -
Long-term debt less current portion	2,800,873	1,824,789	1,837,580	1,838,133	1,742,578
Current portion of finance leases	1,288	1,173	1,108	1,103	1,339
Finance leases less current portion	29,883	34,939	33,432	33,446	38,014
Total Debt	\$ 2,848,375	\$ 1,860,901	\$ 1,872,120	\$ 1,872,682	\$ 1,781,931
Add: unamortized debt issuance costs and debt discounts	73,677	38,761	26,579	25,417	20,972
Less: cash and cash equivalents	(63,025)	(102,454)	(108,016)	(156,224)	(114,919)
Total Net Debt	\$ 2,859,027	\$ 1,797,208	\$ 1,790,683	\$ 1,741,875	\$ 1,687,984
Adjusted EBITDA	\$ 379,932	\$ 419,859	\$ 433,294	\$ 453,431	\$ 469,616
Net Leverage	7.5x	4.3x	4.1x	3.8x	3.6x

(1) For a reconciliation of GAAP to non-GAAP results, please refer to Non-GAAP Financial Measures provided on the following slide.

Non-GAAP Financial Measures

(unaudited) (\$'s in thousands, except per share amounts)	Year Ended December 31,			Twelve Months Ended March 31,	Twelve Months Ended June 30,	Twelve Months Ended September 30,
	2018	2019	2020	2021	2021	2021
Net (loss) income	\$ (5,876)	\$ (20,425)	\$ (37,491)	\$ (24,440)	\$ 10,922	\$ 37,738
Amortization of intangible assets	79,906	80,048	80,255	82,624	84,691	85,730
Impairment of long-lived assets and intangible assets ^(a)	85,067	5,792	—	—	—	—
Gain on sale of Medical Isotopes business ^(b)	(95,910)	—	—	—	—	—
Share-based compensation ^(c)	6,943	16,882	10,987	12,711	14,811	17,457
Capital restructuring bonuses ^(d)	—	2,040	2,702	2,702	2,702	2,702
(Gain) loss on foreign currency and embedded derivatives ^(e)	14,095	2,662	(8,454)	(13,057)	(10,632)	(2,778)
Acquisition and divestiture related charges, net ^(d)	1,168	(318)	3,932	2,753	2,240	(1,041)
Business optimization project expenses ^(g)	8,805	4,195	2,524	1,736	1,265	820
Plant closure expenses ^(h)	—	1,712	2,649	2,420	2,724	1,825
Loss on extinguishment of debt ⁽ⁱ⁾	—	30,168	44,262	58,574	58,575	64,939
Professional services relating to EO sterilization facilities ^(j)	4,739	11,216	36,671	45,924	47,076	44,793
Accretion of asset retirement obligation ^(k)	1,366	2,051	1,946	2,007	2,117	2,221
COVID-19 expenses ^(l)	—	—	2,677	2,900	815	910
Income tax benefit associated with pre-tax adjustments ^(m)	(24,988)	(35,637)	(43,536)	(49,962)	(50,172)	(51,454)
Adjusted Net Income	75,315	100,386	99,124	126,892	167,134	203,862
Interest expense, net	143,326	157,729	215,259	179,979	143,892	106,702
Depreciation ⁽ⁿ⁾	66,910	66,671	63,309	62,578	62,938	63,432
Income tax provision applicable to Adjusted Net Income ^(o)	55,086	55,146	42,167	63,845	79,467	95,620
Adjusted EBITDA^(p)	\$ 340,637	\$ 379,932	\$ 419,859	\$ 433,294	\$ 453,431	\$ 469,616
Net Revenues	\$ 746,149	\$ 778,327	\$ 818,158	\$ 842,106	\$ 880,938	\$ 907,074
Adjusted EBITDA Margin	45.7 %	48.8 %	51.3 %	51.5 %	51.5 %	51.8 %
Weighted average number of shares outstanding	232,400	232,400	237,696			
Basic and diluted EPS	\$ (0.03)	\$ (0.09)	\$ (0.16)			
Adjusted EPS	\$ 0.32	\$ 0.43	\$ 0.42			

Non-GAAP Financial Measures

- (a) Represents impairment charges related to the decision to not reopen the Willowbrook, Illinois facility in September 2019. For 2018, represents impairment charges associated with the withdrawal of the GA-MURR project.
- (b) Represents the gain on the divestiture of the Medical Isotopes business in July 2018.
- (c) Includes non-cash share-based compensation expense. 2019 also includes \$10.0 million of one-time cash share-based compensation expense related to the pre-IPO Class C Units, which vested in the third quarter of 2019.
- (d) Represents cash bonuses for members of management primarily relating to the November 2020 IPO and the December 2019 refinancing.
- (e) Represents the effects of (i) fluctuations in foreign currency exchange rates, primarily related to remeasurement of intercompany loans denominated in currencies other than subsidiaries' functional currencies, and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
- (f) Represents (i) certain direct and incremental costs related to the acquisitions of the noncontrolling interests in our China subsidiaries, BioScience Labs in 2021, Iotron Industries in July 2020, Gibraltar Laboratories, Inc. ("Nelson Labs Fairfield") in 2018 (including the first quarter 2021 gain on the mandatorily redeemable noncontrolling interest), Toxikon Europe, NV ("Nelson Europe") in 2017, and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018, (iv) a \$3.4 million gain recognized in the third quarter of 2021 related to the settlement of an insurance claim for Nordion that existed at the time of our acquisition of the business in 2014.
- (g) Represents professional fees, contract termination and exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integrations of Nordion and Nelson Labs, including the divestiture of Medical Isotopes, the withdrawal from the GA-MURR project, the Sotera Health rebranding, operating structure realignment and other process enhancement projects.
- (h) Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility.
- (i) Represents expenses incurred in connection with the refinancing of our debt capital structure in December 2019, paydown of debt following the November 2020 IPO, the January 2021 Term Loan repricing, and full redemption of the First Lien Notes in August 2021 including accelerated amortization of prior debt issuance and discount costs, and premiums paid in connection with early extinguishment.
- (j) Represents professional fees related to litigation associated with our EO sterilization facilities and other related professional fees.
- (k) Represents non-cash accretion of asset retirement obligations related to Co-60 and gamma processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities (without regard for whether the decommissioning services would be performed by employees of Nordion, instead of by a third party) and are accreted over the life of the asset.
- (l) Represents non-recurring costs associated with the COVID-19 pandemic, including donations to related charitable causes, special bonuses for front-line personnel working on-site during lockdown periods, and incremental costs to implement workplace health and safety measures.
- (m) Represents the tax benefit or provision associated with the reconciling items between net loss and Adjusted Net Income. To determine the aggregate tax effect of the reconciling items, we utilized statutory income tax rates ranging from 0% to 35%, depending upon the applicable jurisdictions of each adjustment.
- (n) Includes depreciation of Co-60 held at gamma irradiation sites.
- (o) Represents the difference between income tax expense or benefit as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (m).
- (p) \$83.8 million, \$86.7 million, \$82.6 million, \$82.3 million, \$84.5 million, \$83.9 million of the adjustments for the twelve months ended December 31, 2018, December 31, 2019, December 31, 2020, March 31, 2021, June 30, 2021, and September 30, 2021, respectively, are included in cost of revenues, primarily consisting of amortization of intangibles, depreciation, and accretion of asset retirement obligations.